Ambrx, Inc.
Ambrx, Inc.
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-06-11 | NCT06224673 | |
| ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-03-09 | NCT04829604 |